The first-line treatment for patients with unresectable metastatic colorectal cancer is chemotherapy in combination with bevacizumab. Emerging evidence, however, suggests that the addition of cetuximab—an anti-EGFR monoclonal antibody—to chemotherapy might be beneficial to patients with wild-type KRAS tumors.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial
Cancer Communications Open Access 24 May 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).
Arnold, D. et al. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer; A phase Ib/II study of the AIO GI group. Ann. Oncol. 19, 1442–1449 (2008).
Tabernero, J. et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 25, 5225–5232 (2007).
Bokemeyer, C. et al. Fluorouracil, leucovorin and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663–671 (2008).
Jimeno, A. et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J. Clin. Oncol. 27, 1130–1136 (2009).
Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N. Engl. J. Med. 360, 1408–17 (2009).
Tol, J. et al. Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer, N. Engl. J. Med. 360, 563–572 (2009).
Hecht, J. R. et al. A Randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27, 672–680 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Sharlene Gill declares she is a consultant for Roche (Canada), and is on the speakers bureau for Amgen, Bristol Myers-Squib and Roche (Canada).
Richard Goldberg declares that he is a consultant for Amgen, BMS and Sanofi Avantis.
Rights and permissions
About this article
Cite this article
Gill, S., Goldberg, R. Cetuximab, chemotherapy and KRAS status in mCRC. Nat Rev Clin Oncol 6, 379–380 (2009). https://doi.org/10.1038/nrclinonc.2009.83
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.83
This article is cited by
-
CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial
Cancer Communications (2019)
-
Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
Immunologic Research (2011)
